| $30K | Jupiter Biomedical Research, Inc.Jupiter Biomedical Research is a preclinical | | Therapeutics | SEC Form D |
| $5.5M | Evia BioEvia Bio’s cryopreservation technology enables the entire Cell Therapy supply chain with high product yield, efficacy | | Therapeutics | SEC Form D |
| $1.8M | Argonaute RNADeveloping safe and reliable methods of temporarily silencing target genes in different tissue cells. | | Therapeutics | SEC Form D |
| $1.5M | Aqur BiosciencesRevolutionizing cardiovascular health with breakthrough science. | | Therapeutics | SEC Form D |
| $7.8M | 3Helix Inc3Helix's Collagen Hybridizing Peptides (CHP) can specifically bind to unfolded collagen molecules | | Diagnostics | SEC Form D |
| $1.1M | Retham TechnologiesRetham Technologies seeks to revolutionize the diagnosis of Heparin induced thrombocytopenia (HIT) by enabling rapid | | Diagnostics | SEC Form D |
| $350K | LLab AngelusLab Angelus builds the connective tissue of precision oncology — coordinating the laboratories, the clinicians | | Diagnostics | SEC Form D |
| $8.6M | Hyku Biosciences Inc.Hyku Biosciences is developing the next generation of small molecule medicines by targeting histidine, tyrosine | | Therapeutics | SEC Form D |
| $1.3M | Bullseye Biodevices, Inc.Bullseye Biodevices offers innovative biosensing devices for disease diagnosis. | | Diagnostics | SEC Form D |
| $5K | MedServ Marketplace Inc.MedServ Marketplace connects healthcare facilities with vetted biomedical, dental, veterinary | | Research tools | SEC Form D |
| $1.7M | ORF BiologicsORF Biologics pioneers next-generation biologics and cutting-edge technologies for research | | Therapeutics | SEC Form D |
| $92.7M | GeorgiamuneRegulating signaling pathways to restore immune homeostasis to fight cancer and autoimmune diseases. | | Therapeutics | SEC Form D |
| $1.0M | IImmuNovusMechanistic immune models and AI-assisted simulation designed to make immune complexity more predictable, explainable | | Research tools | SEC Form D |
| $9.8M | PluristyxPluristyx provides cell therapy solutions to support the manufacturing and development of custom stem cell products. | | Therapeutics | SEC Form D |
| $4.3M | Quantelix | | Diagnostics | SEC Form D |
| $3.0M | BioGene TherapeuticsBioGene Therapeutics is at the forefront of developing novel therapeutic solutions for metabolic disorders. | | Therapeutics | SEC Form D |
| $4.0M | Peptaris, Inc.Peptaris is building an AI-powered platform to design peptides with the properties they need to become viable medicines. | | Therapeutics | SEC Form D |
| $30K | Lakril TechnologiesLåkril Technologies catalyzes sustainability in chemical processes through sales of acrylics | | Synthetic biology | SEC Form D |
| $991K | MBQ PharmaPrecision Targeting GTPases in Cancer, Autoimmunity and Fibrosis Precision Targeting GTPases in Cancer, Autoimmunity | | Therapeutics | SEC Form D |
| $6.6M | OncoSynergyNext generation immunotherapies | | Therapeutics | SEC Form D |
| $1.5M | Remedium BioWe believe that any disease can be cured. | | Therapeutics | SEC Form D |
| $475K | ProteinIQProteinIQ.io is a browser-based bioinformatics platform for protein folding, docking, design, sequence analysis | | Research tools | SEC Form D |
| $29.0M | CresilonOur plant-based technology stops traumatic and surgical bleeds in seconds without the need for manual pressure. | | Therapeutics | SEC Form D |
| $505K | QentorosQentoros develops BIO-PLY™ and a growing pipeline of platelet-derived biologics for high-impact equine conditions. | | Therapeutics | SEC Form D |
| $1.7M | Uniform Bio, Inc.MOSgen turns your samples into MOS: miniaturized, pipetteable 3D models that work wherever organoids do | | Synthetic biology | SEC Form D |
| $175K | SStromaGenesisBetter Cancer Diagnostic and Prognostic Testing for Better Outcomes | | Diagnostics | SEC Form D |
| $11.2M | Pearl DiagnosticsPearl Diagnostics is changing the way clinicians diagnose lung infections. | | Diagnostics | SEC Form D |
| $2.3M | Canal BiosciencesLearn how Canal's TrueLink® NGS technology safeguards your template without the need for end repair. | | Synthetic biology | SEC Form D |
| $34.8M | InstyllaInstylla delivers next-generation liquid embolics for interventional radiology | | Therapeutics | SEC Form D |
| $2.9M | Resolute ScienceDeveloping a novel class of cancer therapeutics for solid tumors. | | Therapeutics | SEC Form D |